SiBone (NASDAQ:SIBN – Get Free Report) CEO Laura Francis sold 1,901 shares of the company’s stock in a transaction that occurred on Tuesday, November 17th. The shares were sold at an average price of $23.18, for a total value of $44,065.18. Following the completion of the sale, the chief executive officer owned 351,275 shares in the company, valued at approximately $8,142,554.50. This represents a 0.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Laura Francis also recently made the following trade(s):
- On Monday, November 16th, Laura Francis sold 14,953 shares of SiBone stock. The stock was sold at an average price of $23.33, for a total transaction of $348,853.49.
- On Wednesday, November 4th, Laura Francis sold 75,000 shares of SiBone stock. The shares were sold at an average price of $25.30, for a total transaction of $1,897,500.00.
- On Monday, October 12th, Laura Francis sold 38,006 shares of SiBone stock. The stock was sold at an average price of $20.05, for a total value of $762,020.30.
- On Monday, August 24th, Laura Francis sold 25,972 shares of SiBone stock. The stock was sold at an average price of $20.12, for a total transaction of $522,556.64.
- On Friday, August 21st, Laura Francis sold 3,923 shares of SiBone stock. The shares were sold at an average price of $20.02, for a total value of $78,538.46.
- On Thursday, August 20th, Laura Francis sold 51,884 shares of SiBone stock. The stock was sold at an average price of $19.46, for a total transaction of $1,009,662.64.
SiBone Trading Up 1.6%
Shares of SiBone stock traded up $0.38 during trading on Wednesday, reaching $23.54. 1,120,107 shares of the company were exchanged, compared to its average volume of 644,914. The company has a quick ratio of 6.15, a current ratio of 7.58 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $1.06 billion, a price-to-earnings ratio of -75.93 and a beta of 0.64. The business has a 50-day moving average price of $20.56 and a 200-day moving average price of $16.85. SiBone has a twelve month low of $11.48 and a twelve month high of $25.92.
SiBone (NASDAQ:SIBN – Get Free Report) last announced its quarterly earnings results on Monday, November 2nd. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.05. The business had revenue of $55.70 million for the quarter, compared to the consensus estimate of $55.31 million. SiBone had a negative net margin of 6.20% and a negative return on equity of 7.57%. Sell-side analysts anticipate that SiBone will post -0.34 EPS for the current fiscal year.
Institutional Trading of SiBone
A number of institutional investors and hedge funds have recently bought and sold shares of SIBN. Versant Capital Management Inc lifted its stake in shares of SiBone by 102.9% in the second quarter. Versant Capital Management Inc now owns 1,749 shares of the company’s stock worth $29,000 after acquiring an additional 887 shares during the period. State of Wyoming increased its position in SiBone by 70.8% in the 1st quarter. State of Wyoming now owns 10,832 shares of the company’s stock valued at $137,000 after buying an additional 4,490 shares in the last quarter. Inceptionr LLC acquired a new position in shares of SiBone during the first quarter worth approximately $156,000. ADAR1 Capital Management LLC acquired a new position in shares of SiBone during the first quarter valued at about $159,000. Finally, Pathstone Holdings LLC purchased a new stake in SiBone in the 3rd quarter valued at $346,000. 98.11% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several equities research analysts recently commented on SIBN shares. Needham & Company LLC cut their price objective on shares of SiBone from $27.00 to $26.00 and set a “buy” rating on the stock in a research report on Tuesday, November 3rd. Wall Street Zen upgraded SiBone from a “hold” rating to a “buy” rating in a research note on Saturday, November 7th. Weiss Ratings raised SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 20th. Citigroup reaffirmed a “market outperform” rating on shares of SiBone in a report on Tuesday, November 3rd. Finally, Truist Financial upped their price objective on shares of SiBone from $23.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday, October 14th. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, SiBone presently has an average rating of “Moderate Buy” and a consensus price target of $25.00.
View Our Latest Stock Report on SiBone
About SiBone
SI-BONE, Inc. is a medical technology company focused on surgical solutions for conditions affecting the sacroiliac (SI) joint and related pelvic anatomy. Founded in 2008, the company develops implants and instruments used by surgeons in procedures involving the SI joint. Its products include the iFuse Implant System, a minimally invasive approach to SI joint fusion, along with related implant systems designed for SI joint and pelvic fixation procedures. SI-BONE also offers surgical instruments and training resources for healthcare professionals.
Featured Stories
- Five stocks we like better than SiBone
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for SiBone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SiBone and related companies with MarketBeat.com's FREE daily email newsletter.
